May 28, 2021
Amid an era of rapid growth, Genmab retained The Chase Group to secure a new clinical development medical executive as they work to pioneer the next generation of antibody platforms to transform the future of cancer treatment. The Chase Group executed the search with expertise by utilizing their proven process and consistent communication. Their insight provided an initial slate of high-quality candidates and the search was completed in an expedited time frame by securing the successful placement of Dr. Teng Jin Ong as the Vice President, Multi-Compound Medical Head, Solid Tumors. Equipped with a surgical background and 16+ years of clinical development experience, Dr. Ong will be a key driver for Genmab’s future. The pipeline, flexibility, and room for new growth at Genmab have the potential to improve the lives of patients living with cancer, aligning with Ong’s primary professional goal to advance treatment options for patients. The Chase Group congratulates Genmab on the incredible addition of Dr. Ong to their clinical development leadership team and anticipate great advancements. If you seek a strong partnership with your executive search firm, we welcome an opportunity to work with you. Let us help you build your leadership team and experience the impact The Chase Group can have on your company’s success/growth. To learn more, email
karen@chasegroup.com.
